Replies to post #102993 on Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

James:

We all know the company cannot cut any more meat -- they'are down to 25 headcount. They literally cut it to the bone...

As for paying for the Aim2Cerv, I found this in the last 10-Q:

During each of the nine months ended July 31, 2019 and 2018, the Company recorded $0.25 million in revenue for the annual license fee renewal. Since Advaxis has no significant obligation to perform after the license transfer and has provided GBP with the right to use its intellectual property, performance is satisfied when the license renews. In addition, GBP paid $2.25 million to the contract research organization that manages the Company’s AIM2CERV clinical trial. On June 27, 2019, Advaxis announced that it is closing the AIM2CERV Phase 3 clinical trial with AXAL in high-risk locally advanced cervical cancer.

Global BioPharma shouldered a big chunk of the expenses.